Tae Wook Kim1, Gwang Ha Kim2,3, Do Youn Park4, Sangjeong Ahn4, Won Lim1, Bon Eun Lee1, Geun Am Song1. 1. Department of Internal Medicine, Pusan National University School of Medicine, 179, Gudeok-ro, Seo-Gu, Busan, 49241, Korea. 2. Department of Internal Medicine, Pusan National University School of Medicine, 179, Gudeok-ro, Seo-Gu, Busan, 49241, Korea. doc0224@pusan.ac.kr. 3. Biomedical Research Institute, Pusan National University Hospital, 179, Gudeok-ro, Seo-Gu, Busan, 49241, Korea. doc0224@pusan.ac.kr. 4. Department of Pathology, Pusan National University School of Medicine, 179, Gudeok-ro, Seo-Gu, Busan, 49241, Korea.
Abstract
BACKGROUND: Subepithelial tumors (SETs) in the gastrointestinal tract are often incidentally found during endoscopic examinations. Although the utility and safety of endoscopic resection (ER) of SETs in the esophagus and stomach have been described, data about the ER of duodenal SETs remain scant. Therefore, we aimed to investigate the clinical outcomes associated with the ER of duodenal SETs and to assess possible predictive factors for incomplete resection. METHODS: We conducted a retrospective observational study of 62 patients (64 lesions) that underwent ER of duodenal SETs between June 2005 and December 2015 at the Pusan National University Hospital. The therapeutic outcomes from ER and procedure-related complications were analyzed. RESULTS: Endoscopic mucosal resection (EMR) was performed in 38 tumors, EMR with a ligation device (EMR-L) in 18 and endoscopic submucosal dissection (ESD) in 8. The overall en bloc resection and complete ER rates were 96.9 % (62/64) and 100 % (64/64), respectively. The complete pathologic resection rate was 76.6 % (49/64). Multivariate logistic regression analyses determined that the macroscopic type (Yamada type I or II; odds ratio [OR] 6.460, 95 % confidence interval [CI] 1.569-37.458, p = 0.027) and the treatment method (ESD; OR 7.178, 95 % CI 1.291-39.323, p = 0.024) were independently associated with incomplete pathologic resection. The procedure-related bleeding and perforation rates were 6.3 % and 4.7 %, respectively. No recurrences were observed in patients who had undergone complete ER at a median follow-up period of 20 months (range 6-112 months). CONCLUSION: ER is an effective, safe, and feasible treatment for duodenal SETs, especially when the SET is located in the deep mucosal layer and/or the submucosal layer.
BACKGROUND:Subepithelial tumors (SETs) in the gastrointestinal tract are often incidentally found during endoscopic examinations. Although the utility and safety of endoscopic resection (ER) of SETs in the esophagus and stomach have been described, data about the ER of duodenal SETs remain scant. Therefore, we aimed to investigate the clinical outcomes associated with the ER of duodenal SETs and to assess possible predictive factors for incomplete resection. METHODS: We conducted a retrospective observational study of 62 patients (64 lesions) that underwent ER of duodenal SETs between June 2005 and December 2015 at the Pusan National University Hospital. The therapeutic outcomes from ER and procedure-related complications were analyzed. RESULTS: Endoscopic mucosal resection (EMR) was performed in 38 tumors, EMR with a ligation device (EMR-L) in 18 and endoscopic submucosal dissection (ESD) in 8. The overall en bloc resection and complete ER rates were 96.9 % (62/64) and 100 % (64/64), respectively. The complete pathologic resection rate was 76.6 % (49/64). Multivariate logistic regression analyses determined that the macroscopic type (Yamada type I or II; odds ratio [OR] 6.460, 95 % confidence interval [CI] 1.569-37.458, p = 0.027) and the treatment method (ESD; OR 7.178, 95 % CI 1.291-39.323, p = 0.024) were independently associated with incomplete pathologic resection. The procedure-related bleeding and perforation rates were 6.3 % and 4.7 %, respectively. No recurrences were observed in patients who had undergone complete ER at a median follow-up period of 20 months (range 6-112 months). CONCLUSION: ER is an effective, safe, and feasible treatment for duodenal SETs, especially when the SET is located in the deep mucosal layer and/or the submucosal layer.
Authors: Hye Jin Tae; Hang Lak Lee; Kang Nyeong Lee; Dae Won Jun; Oh Young Lee; Dong Soo Han; Byung Chul Yoon; Ho Soon Choi; Joon Soo Hahm Journal: Endoscopy Date: 2014-08-11 Impact factor: 10.093
Authors: H Inoue; H Ikeda; T Hosoya; M Onimaru; A Yoshida; N Eleftheriadis; R Maselli; S Kudo Journal: Endoscopy Date: 2012-02-21 Impact factor: 10.093
Authors: Sina Alexander; Michael J Bourke; Stephen J Williams; Adam Bailey; Jonard Co Journal: Gastrointest Endosc Date: 2008-08-23 Impact factor: 9.427